Rhythm Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Rhythm Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 91% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 89% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 88% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$20For every $100 of sales, $20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $18 tied up three years earlier.
Less money tied up than 58% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$9Sales grew 703% in 3 years, but profit fell: $9 less profit per $100 of extra sales.
Lower than 74% of Healthcare companies in United States.
Asset Productivity Ratio
+703% / +26%In 3 years sales changed by +703% while total assets changed by +26%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-178.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 91% of Healthcare companies in United States.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Lower than 55% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 88% of Healthcare companies in United States.
Tangible Net Worth Ratio
98%Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 89% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Rhythm Pharmaceuticals, Inc. made a loss over the last year. Rhythm Pharmaceuticals, Inc. owes $0.50 for every $1 it owns. Rhythm Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRhythm Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
28.80The share price is 28.80 times Rhythm Pharmaceuticals, Inc.'s book value per share, higher than 96% of Healthcare companies in United States.
Market cap
$6.3 BThe total market value of all of Rhythm Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 86% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$217 MWhat Rhythm Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.16Net worth divided by the number of shares. The share price of $90.90 is 28.8 times this, which is the P/B above.
Return on equity (ROE)
-117.0%Rhythm Pharmaceuticals, Inc. lost 117.0% of its shareholders' money over the last year, lower than 75% of Healthcare companies in United States.
Owes vs Owns
0.50×Rhythm Pharmaceuticals, Inc. owes $0.50 for every $1 it owns (moderate), higher than 56% of Healthcare companies in United States.
Dividend yield
NoneRhythm Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+46%Revenue rose 46% in the year to Dec 2025, and grew 100% a year on average over 3 years.
Profit growth
LossRhythm Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-103.6%Rhythm Pharmaceuticals, Inc. lost $104 for every $100 of revenue.
Interest cover
Not coveredRhythm Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashRhythm Pharmaceuticals, Inc. held $385 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rhythm Pharmaceuticals, Inc.: $6.3 B ÷ $217 M (30 Jun 2026) = 28.8.
What is Rhythm Pharmaceuticals, Inc.'s return on equity?
Rhythm Pharmaceuticals, Inc. lost 117.0% of its shareholders' money over the last year, lower than 75% of Healthcare companies in United States.
How much does Rhythm Pharmaceuticals, Inc. owe compared with what it owns?
Rhythm Pharmaceuticals, Inc. owes $0.50 for every $1 it owns (moderate), higher than 56% of Healthcare companies in United States.
Does Rhythm Pharmaceuticals, Inc. pay a dividend?
No. Rhythm Pharmaceuticals, Inc. does not currently pay a dividend.
Is Rhythm Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 46% in the year to Dec 2025, and grew 100% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.